Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-057424
Filing Date
2023-11-01
Accepted
2023-11-01 16:05:35
Documents
68
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nmra-20230930.htm   iXBRL 10-Q 2750799
2 EX-31.1 nmra-ex31_1.htm EX-31.1 19644
3 EX-31.2 nmra-ex31_2.htm EX-31.2 19637
4 EX-32.1 nmra-ex32_1.htm EX-32.1 11754
5 EX-32.2 nmra-ex32_2.htm EX-32.2 11676
6 GRAPHIC img234928740_0.jpg GRAPHIC 33628
  Complete submission text file 0000950170-23-057424.txt   9891737

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nmra-20230930_pre.xml EX-101.PRE 350115
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nmra-20230930_def.xml EX-101.DEF 219304
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nmra-20230930_cal.xml EX-101.CAL 36726
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nmra-20230930_lab.xml EX-101.LAB 449224
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nmra-20230930.xsd EX-101.SCH 58094
62 EXTRACTED XBRL INSTANCE DOCUMENT nmra-20230930_htm.xml XML 1901452
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41802 | Film No.: 231368195
SIC: 2836 Biological Products, (No Diagnostic Substances)